Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenberg, M. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rosenberg, M. G.

Antibiotic Drug Levels

Michael G. Rosenberg MD, PhD1
1 Department of Pediatrics, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Editors: Henry M. Adam, MD.

In the past, efficacy, as defined by controlled clinical trials, was the primary factor in the selection of a particular antibiotic regimen. Today, as the number of antimicrobial agents approved for clinical use has grown almost exponentially, efficacy rarely is emphasized in published clinical trials. More commonly they demonstrate therapeutic equivalence rather than superiority of new compounds to previously accepted regimens. For this reason, the two criteria that now factor most prominently into the selection of equally effective antibiotics are relative toxicity and cost.

Three major classes of antibiotics used throughout the world in the treatment of serious pediatric infectious diseases are chloramphenicol (CAP) and its derivatives, aminoglycosides (AGs), and vancomycin and related glycopeptides.







HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics  Pediatrics in Review
Copyright © 1995 by the American Academy of Pediatrics.